ABBV-744 as a potential therapeutic option for aggressive cancers Secrets
In Segment C, members will receive ABBV-744 and oral navitoclax. In Section D, participants will obtain ABBV-744 and ruxolitinib. Contributors will receive treatment right up until condition progression or the individuals are unable to tolerate the study drugs.There might be bigger treatment burden for contributors On this trial in comparison to th